Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/24/2023 | 862.03% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
07/13/2023 | 862.03% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
05/24/2023 | 406.33% | Alliance Global Partners | → $20 | Reiterates | → Buy |
11/14/2022 | 51.9% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
11/08/2022 | 912.66% | Cantor Fitzgerald | $22 → $40 | Maintains | Overweight |
08/11/2022 | 26.58% | SVB Leerink | $1 → $5 | Maintains | Market Perform |
11/30/2021 | -74.68% | SVB Leerink | $5 → $1 | Downgrades | Outperform → Market Perform |
11/29/2021 | 1.27% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
07/19/2021 | 26.58% | HC Wainwright & Co. | $8 → $5 | Maintains | Buy |
11/25/2020 | 102.53% | HC Wainwright & Co. | $11 → $8 | Maintains | Buy |
11/11/2020 | 1.27% | Cantor Fitzgerald | → $4 | Upgrades | Neutral → Overweight |
11/10/2020 | 26.58% | SVB Leerink | $8 → $5 | Maintains | Outperform |
09/18/2020 | 26.58% | B. Riley Securities | → $5 | Initiates Coverage On | → Buy |
05/08/2020 | 77.22% | RBC Capital | $11 → $7 | Maintains | Outperform |
03/18/2020 | 178.48% | RBC Capital | $14 → $11 | Maintains | Outperform |
02/10/2020 | 51.9% | SVB Leerink | → $6 | Maintains | Outperform |
12/30/2019 | 178.48% | HC Wainwright & Co. | $15 → $11 | Reiterates | → Buy |
08/15/2019 | — | Maxim Group | Downgrades | Buy → Hold | |
08/12/2019 | -49.37% | Cantor Fitzgerald | $29 → $2 | Downgrades | Overweight → Neutral |
08/12/2019 | 279.75% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
07/26/2019 | — | Mizuho | Downgrades | Buy → Neutral | |
11/13/2018 | 608.86% | Citigroup | $32 → $28 | Maintains | Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/24/2023 | 862.03% | 坎托·菲茨杰拉德 | → 38 美元 | 重申 | 超重 → 超重 |
07/13/2023 | 862.03% | 坎托·菲茨杰拉德 | → 38 美元 | 重申 | 超重 → 超重 |
05/24/2023 | 406.33% | 联盟全球合作伙伴 | → 20 美元 | 重申 | → 购买 |
11/14/2022 | 51.9% | SVB Leerink | 5 美元 → 6 美元 | 维护 | 市场表现 |
2022 年 8 月 11 日 | 912.66% | 坎托·菲茨杰拉德 | 22 美元 → 40 美元 | 维护 | 超重 |
08/11/2022 | 26.58% | SVB Leerink | 1 美元 → 5 美元 | 维护 | 市场表现 |
2021 年 11 月 30 日 | -74.68% | SVB Leerink | 5 美元 → 1 美元 | 降级 | 跑赢大盘 → 市场表现 |
11/29/2021 | 1.27% | HC Wainwright & Co. | 5 美元 → 4 美元 | 维护 | 购买 |
07/19/2021 | 26.58% | HC Wainwright & Co. | 8 美元 → 5 美元 | 维护 | 购买 |
11/25/2020 | 102.53% | HC Wainwright & Co. | 11 美元 → 8 美元 | 维护 | 购买 |
11/11/2020 | 1.27% | 坎托·菲茨杰拉德 | → 4 美元 | 升级 | 中性 → 超重 |
11/10/2020 | 26.58% | SVB Leerink | 8 美元 → 5 美元 | 维护 | 跑赢大盘 |
09/18/2020 | 26.58% | B. 莱利证券 | → 5 美元 | 启动覆盖开启 | → 购买 |
05/08/2020 | 77.22% | 加拿大皇家银行资本 | 11 美元 → 7 美元 | 维护 | 跑赢大盘 |
2020 年 3 月 18 日 | 178.48% | 加拿大皇家银行资本 | 14 美元 → 11 美元 | 维护 | 跑赢大盘 |
2020 年 10 月 2 日 | 51.9% | SVB Leerink | → 6 美元 | 维护 | 跑赢大盘 |
2019 年 12 月 30 日 | 178.48% | HC Wainwright & Co. | 15 美元 → 11 美元 | 重申 | → 购买 |
08/15/2019 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
08/12/2019 | -49.37% | 坎托·菲茨杰拉德 | 29 美元 → 2 美元 | 降级 | 超重 → 中性 |
08/12/2019 | 279.75% | HC Wainwright & Co. | → 15 美元 | 启动覆盖开启 | → 购买 |
07/26/2019 | — | 瑞穗 | 降级 | 买入 → 中性 | |
11/13/2018 | 608.86% | 花旗集团 | 32 美元 → 28 美元 | 维护 | 购买 |
What is the target price for Abeona Therapeutics (ABEO)?
Abeona Therapeutics(ABEO)的目标价格是多少?
The latest price target for Abeona Therapeutics (NASDAQ: ABEO) was reported by Cantor Fitzgerald on August 24, 2023. The analyst firm set a price target for $38.00 expecting ABEO to rise to within 12 months (a possible 862.03% upside). 5 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年8月24日公布了Abeona Therapeutics(纳斯达克股票代码:ABEO)的最新目标股价。该分析公司将目标股价定为38.00美元,预计ABEO将在12个月内上涨至862.03%(可能上涨862.03%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Abeona Therapeutics (ABEO)?
分析师对Abeona Therapeutics(ABEO)的最新评级是多少?
The latest analyst rating for Abeona Therapeutics (NASDAQ: ABEO) was provided by Cantor Fitzgerald, and Abeona Therapeutics reiterated their overweight rating.
Abeona Therapeutics(纳斯达克股票代码:ABEO)的最新分析师评级由坎托·菲茨杰拉德提供,Abeona Therapeutics重申了他们的增持评级。
When is the next analyst rating going to be posted or updated for Abeona Therapeutics (ABEO)?
Abeona Therapeutics(ABEO)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.
分析师在进行了广泛的研究后得出了股票评级,包括阅读公开财务报表、与Abeona Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。Abeona Therapeutics的最后一次评级是在2023年8月24日提交的,因此你应该预计下一个评级将在2024年8月24日左右公布。
Is the Analyst Rating Abeona Therapeutics (ABEO) correct?
分析师对Abeona Therapeutics(ABEO)的评级正确吗?
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Abeona Therapeutics (ABEO) is trading at is $3.95, which is within the analyst's predicted range.
尽管评级是主观的,将会发生变化,但Abeona Therapeutics(ABEO)的最新评级得到了重申,目标股价为0.00美元至38.00美元。Abeona Therapeutics(ABEO)目前的交易价格为3.95美元,在分析师的预测区间内。